Literature DB >> 7178198

Intravenous diazepam in humans: effects on acquisition and performance of response chains.

P J Desjardins, J M Moerschbaecher, D M Thompson, J R Thomas.   

Abstract

A technique based upon an individual-subject design was used to investigate the effects of intravenous diazepam on the acquisition and performance of response chains in humans. In each of two conditions subjects were required to emit a different sequence of ten responses in a predetermined order on three levers. The conditions alternated within each session under a multiple schedule. In the performance condition the sequence of responses was the same each session. The second condition was a repeated-acquisition task. In this condition subjects were required to learn a different sequence of responses each session. Diazepam produced dose-dependent decreases in the overall rate of responding in each subject under both conditions. In two of the three subjects tested, errors were increased in the learning condition at doses lower than those required to disrupt accuracy in the performance condition. In one subject, accuracy in both the learning and performance conditions was equisensitive to the disruptive effects of diazepam. These data are consistent with the effects of the benzodiazepines in analogous animal procedures. Furthermore, the data suggest that the behavioral effects of intravenous diazepam may exhibit marked variations across subjects at clinically relevant doses (5-10 mg).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7178198     DOI: 10.1016/0091-3057(82)90493-2

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  9 in total

1.  Effects of scopolamine on repeated acquisition of radial-arm maze performance by rats.

Authors:  D B Peele; S P Baron
Journal:  J Exp Anal Behav       Date:  1988-03       Impact factor: 2.468

2.  Effects of cocaine and alcohol, alone and in combination, on human learning and performance.

Authors:  S T Higgins; C R Rush; J R Hughes; W K Bickel; M Lynn; M A Capeless
Journal:  J Exp Anal Behav       Date:  1992-07       Impact factor: 2.468

3.  The effects of diazepam and triazolam on repeated acquisition and performance of response sequences with an observing response.

Authors:  W K Bickel; S T Higgins; J R Hughes
Journal:  J Exp Anal Behav       Date:  1991-09       Impact factor: 2.468

4.  Interaction of cocaine with positive GABAA modulators on the repeated acquisition and performance of response sequences in rats.

Authors:  M S Quinton; L R Gerak; J M Moerschbaecher; P J Winsauer
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

5.  Effects of pregnanolone and flunitrazepam on the retention of response sequences in rats.

Authors:  Russell J Amato; Joseph M Moerschbaecher; Peter J Winsauer
Journal:  Pharmacol Biochem Behav       Date:  2011-05-27       Impact factor: 3.533

6.  Repeated diazepam administration: effects on the acquisition and performance of response chains in humans.

Authors:  W K Bickel; S T Higgins; R R Griffiths
Journal:  J Exp Anal Behav       Date:  1989-07       Impact factor: 2.468

7.  Relative potency and effectiveness of flunitrazepam, ethanol, and beta-CCE for disrupting the acquisition and retention of response sequences in rats.

Authors:  Stuart T Leonard; Lisa R Gerak; Marcus S Delatte; Joseph M Moerschbaecher; Peter J Winsauer
Journal:  Behav Pharmacol       Date:  2009-02       Impact factor: 2.293

8.  Effects of atropine on the repeated acquisition and performance of response sequences in humans.

Authors:  S T Higgins; B M Woodward; J E Henningfield
Journal:  J Exp Anal Behav       Date:  1989-01       Impact factor: 2.468

9.  Effects of pregnanolone alone and in combination with other positive GABAA modulators on complex behavior in rats.

Authors:  Lisa R Gerak; Michael W Stevenson; Peter J Winsauer; Joseph M Moerschbaecher
Journal:  Psychopharmacology (Berl)       Date:  2004-01-22       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.